These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 24297113)

  • 1. Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes.
    Saratsis AM; Kambhampati M; Snyder K; Yadavilli S; Devaney JM; Harmon B; Hall J; Raabe EH; An P; Weingart M; Rood BR; Magge SN; MacDonald TJ; Packer RJ; Nazarian J
    Acta Neuropathol; 2014; 127(6):881-95. PubMed ID: 24297113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
    Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
    Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid.
    Saratsis AM; Yadavilli S; Magge S; Rood BR; Perez J; Hill DA; Hwang E; Kilburn L; Packer RJ; Nazarian J
    Neuro Oncol; 2012 May; 14(5):547-60. PubMed ID: 22492959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
    Carceller F; Fowkes LA; Khabra K; Moreno L; Saran F; Burford A; Mackay A; Jones DT; Hovestadt V; Marshall LV; Vaidya S; Mandeville H; Jerome N; Bridges LR; Laxton R; Al-Sarraj S; Pfister SM; Leach MO; Pearson AD; Jones C; Koh DM; Zacharoulis S
    J Neurooncol; 2016 Aug; 129(1):109-21. PubMed ID: 27180091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma.
    Ahsan S; Raabe EH; Haffner MC; Vaghasia A; Warren KE; Quezado M; Ballester LY; Nazarian J; Eberhart CG; Rodriguez FJ
    Acta Neuropathol Commun; 2014 Jun; 2():59. PubMed ID: 24894482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
    Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
    J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics.
    Hoffman LM; DeWire M; Ryall S; Buczkowicz P; Leach J; Miles L; Ramani A; Brudno M; Kumar SS; Drissi R; Dexheimer P; Salloum R; Chow L; Hummel T; Stevenson C; Lu QR; Jones B; Witte D; Aronow B; Hawkins CE; Fouladi M
    Acta Neuropathol Commun; 2016 Jan; 4():1. PubMed ID: 26727948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease.
    Qi J; Esfahani DR; Huang T; Ozark P; Bartom E; Hashizume R; Bonner ER; An S; Horbinski CM; James CD; Saratsis AM
    Acta Neuropathol Commun; 2019 May; 7(1):75. PubMed ID: 31092287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
    Khuong-Quang DA; Buczkowicz P; Rakopoulos P; Liu XY; Fontebasso AM; Bouffet E; Bartels U; Albrecht S; Schwartzentruber J; Letourneau L; Bourgey M; Bourque G; Montpetit A; Bourret G; Lepage P; Fleming A; Lichter P; Kool M; von Deimling A; Sturm D; Korshunov A; Faury D; Jones DT; Majewski J; Pfister SM; Jabado N; Hawkins C
    Acta Neuropathol; 2012 Sep; 124(3):439-47. PubMed ID: 22661320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.
    Zhou Z; Luther N; Ibrahim GM; Hawkins C; Vibhakar R; Handler MH; Souweidane MM
    J Neurooncol; 2013 Feb; 111(3):257-64. PubMed ID: 23232807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
    Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas.
    Dorris K; Sobo M; Onar-Thomas A; Panditharatna E; Stevenson CB; Gardner SL; Dewire MD; Pierson CR; Olshefski R; Rempel SA; Goldman S; Miles L; Fouladi M; Drissi R
    J Neurooncol; 2014 Mar; 117(1):67-76. PubMed ID: 24477622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas.
    Anderson JL; Muraleedharan R; Oatman N; Klotter A; Sengupta S; Waclaw RR; Wu J; Drissi R; Miles L; Raabe EH; Weirauch ML; Fouladi M; Chow LM; Hoffman L; DeWire M; Dasgupta B
    Neuro Oncol; 2017 Aug; 19(8):1068-1078. PubMed ID: 28339768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets.
    Zhu X; Lazow MA; Schafer A; Bartlett A; Senthil Kumar S; Mishra DK; Dexheimer P; DeWire M; Fuller C; Leach JL; Fouladi M; Drissi R
    Acta Neuropathol Commun; 2021 Jan; 9(1):14. PubMed ID: 33431066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
    Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
    Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal Transduction in Diffuse Intrinsic Pontine Glioma.
    Duchatel RJ; Jackson ER; Alvaro F; Nixon B; Hondermarck H; Dun MD
    Proteomics; 2019 Nov; 19(21-22):e1800479. PubMed ID: 31328874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.
    Mendez FM; Núñez FJ; Garcia-Fabiani MB; Haase S; Carney S; Gauss JC; Becher OJ; Lowenstein PR; Castro MG
    Neuro Oncol; 2020 Feb; 22(2):195-206. PubMed ID: 32078691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
    An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.